

Matthias Eiber

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8200963/publications.pdf>

Version: 2024-02-01

179
papers

10,705
citations

36303

51
h-index

34986

98
g-index

181
all docs

181
docs citations

181
times ranked

6545
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of Hybrid ⁶⁸ Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. <i>Journal of Nuclear Medicine</i> , 2015, 56, 668-674.	5.0	907
2	Diagnostic Efficacy of ⁶⁸ Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. <i>Journal of Urology</i> , 2016, 195, 1436-1443.	0.4	659
3	Current use of PSMA- ⁶⁸ PET in prostate cancer management. <i>Nature Reviews Urology</i> , 2016, 13, 226-235.	3.8	469
4	Simultaneous ⁶⁸ Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer. <i>European Urology</i> , 2016, 70, 829-836.	1.9	456
5	⁶⁸ Ga- and ¹⁷⁷ Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1169-1176.	5.0	432
6	¹⁸ F-fluciclovine PET-CT and ⁶⁸ Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. <i>Lancet Oncology</i> , 2019, 20, 1286-1294.	10.7	338
7	Comparison of bone scintigraphy and ⁶⁸ Ga-PSMA PET for skeletal staging in prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2114-2121.	6.4	302
8	Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls. <i>Radiographics</i> , 2018, 38, 200-217.	3.3	262
9	Value of ⁶⁸ Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1713-1719.	5.0	213
10	Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with ¹⁷⁷ Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2019, 75, 920-926.	1.9	206
11	^{99m} Tc-based Prostate-specific Membrane Antigen- ⁶⁸ radioguided Surgery in Recurrent Prostate Cancer. <i>European Urology</i> , 2019, 75, 659-666.	1.9	195
12	Prostate-specific Membrane Antigen- ⁶⁸ radioguided Surgery for Metastatic Lymph Nodes in Prostate Cancer. <i>European Urology</i> , 2015, 68, 530-534.	1.9	192
13	E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1626-1638.	6.4	188
14	<i>In vivo</i> molecular imaging of chemokine receptor ⁴ CXCR expression in patients with advanced multiple myeloma. <i>EMBO Molecular Medicine</i> , 2015, 7, 477-487.	6.9	180
15	Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine. <i>Journal of Nuclear Medicine</i> , 2019, 60, 13S-19S.	5.0	172
16	⁶⁸ Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report. <i>Cancer Imaging</i> , 2016, 16, 14.	2.8	171
17	Preclinical Evaluation and First Patient Application of ^{99m} Tc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 235-242.	5.0	170
18	Systemic Radioligand Therapy with ¹⁷⁷ Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer. <i>Journal of Urology</i> , 2016, 196, 382-391.	0.4	166

#	ARTICLE	IF	CITATIONS
19	PSMA Ligands for PET Imaging of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1545-1552.	5.0	165
20	Matched-Pair Comparison of ⁶⁸ Ga-PSMA-11 PET/CT and ¹⁸ F-PSMA-1007 PET/CT: Frequency of Pitfalls and Detection Efficacy in Biochemical Recurrence After Radical Prostatectomy. <i>Journal of Nuclear Medicine</i> , 2020, 61, 51-57.	5.0	161
21	Radiation Dosimetry for ¹⁷⁷ Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions. <i>Journal of Nuclear Medicine</i> , 2017, 58, 445-450.	5.0	144
22	Efficacy, Predictive Factors, and Prediction Nomograms for ⁶⁸ Ga-labeled Prostate-specific Membrane Antigen- ⁶⁸ Ga-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy. <i>European Urology</i> , 2018, 73, 656-661.	1.9	129
23	Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA. <i>European Urology</i> , 2021, 79, 343-350.	1.9	128
24	Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors. <i>Journal of Experimental Medicine</i> , 2018, 215, 159-175.	8.5	121
25	Nomograms to predict outcomes after ¹⁷⁷ Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. <i>Lancet Oncology</i> , The, 2021, 22, 1115-1125.	10.7	120
26	Head-to-head intra-individual comparison of biodistribution and tumor uptake of ⁶⁸ Ga-FAPI and ¹⁸ F-FDG PET/CT in cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4377-4385.	6.4	114
27	⁶⁸ Ga-PSMA-HBED-CC PET for Differential Diagnosis of Suggestive Lung Lesions in Patients with Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 367-371.	5.0	112
28	First Experience with Chemokine Receptor CXCR4-Targeted PET Imaging of Patients with Solid Cancers. <i>Journal of Nuclear Medicine</i> , 2016, 57, 741-746.	5.0	109
29	Preliminary results on response assessment using ⁶⁸ Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 602-612.	6.4	107
30	⁶⁸ Ga-PSMA-HBED-CC Uptake in Cervical, Celiac, and Sacral Ganglia as an Important Pitfall in Prostate Cancer PET Imaging. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1406-1411.	5.0	106
31	Development of standardized image interpretation for ⁶⁸ Ga-PSMA PET/CT to detect prostate cancer recurrent lesions. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1622-1635.	6.4	91
32	Consensus on molecular imaging and theranostics in prostate cancer. <i>Lancet Oncology</i> , The, 2018, 19, e696-e708.	10.7	90
33	⁶⁸ Ga-PSMA-PET for radiation treatment planning in prostate cancer recurrences after surgery: Individualized medicine or new standard in salvage treatment. <i>Prostate</i> , 2017, 77, 920-927.	2.3	89
34	[¹¹¹ In]PSMA-I&T: expanding the spectrum of PSMA-I&T applications towards SPECT and radioguided surgery. <i>EJNMMI Research</i> , 2015, 5, 68.	2.5	88
35	Value of ¹¹¹ In-prostate-specific membrane antigen (¹¹¹ In-PSMA)-radioguided surgery for salvage lymphadenectomy in recurrent prostate cancer: correlation with histopathology and clinical follow-up. <i>BJU International</i> , 2017, 120, 40-47.	2.5	88
36	qPSMA: Semiautomatic Software for Whole-Body Tumor Burden Assessment in Prostate Cancer Using ⁶⁸ Ga-PSMA11 PET/CT. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1277-1283.	5.0	82

#	ARTICLE	IF	CITATIONS
37	Single Lesion on Prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low Prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to Prostate-specific Membrane Antigen-targeted Radioguided Surgery in Recurrent Prostate Cancer. <i>European Urology</i> , 2019, 76, 517-523.	1.9	81
38	Radiohybrid Ligands: A Novel Tracer Concept Exemplified by ¹⁸ F- or ⁶⁸ Ga-Labeled rhPSMA Inhibitors. <i>Journal of Nuclear Medicine</i> , 2020, 61, 735-742.	5.0	76
39	⁶⁸ Ga-PSMA PET/MR with multimodality image analysis for primary prostate cancer. <i>Abdominal Imaging</i> , 2015, 40, 1769-1771.	2.0	74
40	The use of PET/CT in prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 4-21.	3.9	70
41	Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT). <i>BMC Cancer</i> , 2017, 17, 361.	2.6	67
42	Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 9-15.	6.4	67
43	¹⁸ F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy. <i>Journal of Nuclear Medicine</i> , 2020, 61, 696-701.	5.0	67
44	Biodistribution and radiation dosimetry of ⁶⁸ Ga-PSMA HBED CCâ€”a PSMA specific probe for PET imaging of prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1962-1970.	6.4	66
45	Detection Efficacy of Hybrid ⁶⁸ Ga-PSMA Ligand PET/CT in Prostate Cancer Patients with Biochemical Recurrence After Primary Radiation Therapy Defined by Phoenix Criteria. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1081-1087.	5.0	66
46	Deep neural network for automatic characterization of lesions on ⁶⁸ Ga-PSMA-11 PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 603-613.	6.4	66
47	Technologies for image-guided surgery for managing lymphatic metastases in prostate cancer. <i>Nature Reviews Urology</i> , 2019, 16, 159-171.	3.8	62
48	Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer. <i>EJNMMI Research</i> , 2018, 8, 96.	2.5	58
49	One-Stop-Shop Whole-Body ⁶⁸ Ga-PSMA-11 PET/MRI Compared with Clinical Nomograms for Preoperative T and N Staging of High-Risk Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1850-1856.	5.0	55
50	A machine learning model for the prediction of survival and tumor subtype in pancreatic ductal adenocarcinoma from preoperative diffusion-weighted imaging. <i>European Radiology Experimental</i> , 2019, 3, 41.	3.4	55
51	The Effect of Total Tumor Volume on the Biologically Effective Dose to Tumor and Kidneys for ¹⁷⁷ Lu-Labeled PSMA Peptides. <i>Journal of Nuclear Medicine</i> , 2018, 59, 929-933.	5.0	54
52	Discrimination Between Brown and White Adipose Tissue Using a 2-Point Dixon Waterâ€”Fat Separation Method in Simultaneous PET/MRI. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1742-1747.	5.0	45
53	Performance of [⁶⁸ Ga]Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer after prostatectomyâ€”a multi-centre evaluation of 2533 patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2925-2934.	6.4	43
54	Head-to-Head Comparison of ⁶⁸ Ga-PSMA-11 PET/CT and mpMRI with a Histopathology Gold Standard in the Detection, Intraprostatic Localization, and Determination of Local Extension of Primary Prostate Cancer: Results from a Prospective Single-Center Imaging Trial. <i>Journal of Nuclear Medicine</i> , 2022, 63, 847-854.	5.0	43

#	ARTICLE	IF	CITATIONS
55	Radical Prostatectomy Without Prior Biopsy Following Multiparametric Magnetic Resonance Imaging and Prostate-specific Membrane Antigen Positron Emission Tomography. <i>European Urology</i> , 2022, 82, 156-160.	1.9	43
56	Prospective evaluation of [¹¹ C]Choline PET/CT in therapy response assessment of standardized docetaxel first-line chemotherapy in patients with advanced castration refractory prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2105-2113.	6.4	42
57	Tumor Sink Effect in ⁶⁸ Ga-PSMA-11 PET: Myth or Reality?. <i>Journal of Nuclear Medicine</i> , 2022, 63, 226-232.	5.0	42
58	Modeling and Predicting Tumor Response in Radioligand Therapy. <i>Journal of Nuclear Medicine</i> , 2019, 60, 65-70.	5.0	41
59	Efficacy and Safety of ¹⁷⁷ Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study. <i>European Urology</i> , 2020, 78, 148-154.	1.9	39
60	Quantitative and Qualitative Analyses of Biodistribution and PET Image Quality of a Novel Radiohybrid PSMA, ¹⁸ F-rhPSMA-7, in Patients with Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 702-709.	5.0	38
61	Prostate-specific Membrane Antigen PET in Prostate Cancer. <i>Radiology</i> , 2021, 299, 248-260.	7.3	38
62	The added value of PSMA PET/MR radiomics for prostate cancer staging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 527-538.	6.4	38
63	Imaging for Prostate Cancer Recurrence. <i>European Urology Focus</i> , 2016, 2, 139-150.	3.1	36
64	Matched-Pair Comparison of ⁶⁸ Ga-PSMA-11 and ¹⁸ F-rhPSMA-7 PET/CT in Patients with Primary and Biochemical Recurrence of Prostate Cancer: Frequency of Non- ⁶⁸ Tumor-Related Uptake and Tumor Positivity. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1082-1088.	5.0	36
65	Prospective head-to-head comparison of ¹¹ C-choline-PET/MR and ¹¹ C-choline-PET/CT for restaging of biochemical recurrent prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 2179-2188.	6.4	35
66	Histologically Confirmed Diagnostic Efficacy of ¹⁸ F-rhPSMA-7 PET for N-Staging of Patients with Primary High-Risk Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 710-715.	5.0	34
67	Early Prostate-Specific Antigen Changes and Clinical Outcome After ¹⁷⁷ Lu-PSMA Radionuclide Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1476-1483.	5.0	34
68	Prostate-specific Membrane Antigen Positron Emission Tomography-detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation. <i>European Urology Focus</i> , 2021, 7, 309-316.	3.1	34
69	Exploring New Multimodal Quantitative Imaging Indices for the Assessment of Osseous Tumor Burden in Prostate Cancer Using ⁶⁸ Ga-PSMA PET/CT. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1632-1637.	5.0	33
70	Synthesis and preclinical evaluation of novel ¹⁸ F-labeled Glu-urea-Glu-based PSMA inhibitors for prostate cancer imaging: a comparison with ¹⁸ F-DCFPyl and ¹⁸ F-PSMA-1007. <i>EJNMMI Research</i> , 2018, 8, 30.	2.5	33
71	⁶⁸ Ga-PSMA-11 Positron Emission Tomography Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective Study. <i>Journal of Urology</i> , 2019, 202, 1174-1181.	0.4	33
72	Prostate-Specific Membrane Antigen-Guided Surgery. <i>Journal of Nuclear Medicine</i> , 2020, 61, 6-12.	5.0	31

#	ARTICLE	IF	CITATIONS
73	PSMA-PET/CT-based Lymph Node Atlas for Prostate Cancer Patients Recurring After Primary Treatment: Clinical Implications for Salvage Radiation Therapy. <i>European Urology Oncology</i> , 2021, 4, 73-83.	5.4	30
74	Early Experience of Rechallenge ¹⁷⁷ Lu-PSMA Radioligand Therapy After an Initial Good Response in Patients with Advanced Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2019, 60, 644-648.	5.0	29
75	Detection of Circulating Tumor Cells in Locally Advanced High-risk Prostate Cancer During Neoadjuvant Chemotherapy and Radical Prostatectomy. <i>Anticancer Research</i> , 2015, 35, 5679-85.	1.1	29
76	Novel technology of molecular radio-guidance for lymph node dissection in recurrent prostate cancer by PSMA-ligands. <i>World Journal of Urology</i> , 2018, 36, 603-608.	2.2	28
77	The effect of ligand amount, affinity and internalization on PSMA-targeted imaging and therapy: A simulation study using a PBPK model. <i>Scientific Reports</i> , 2019, 9, 20041.	3.3	28
78	Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study. <i>Journal of Nuclear Medicine</i> , 2022, , jnumed.121.263072.	5.0	28
79	⁶⁸ Ga-PSMA PET/CT and Volumetric Morphology of PET-Positive Lymph Nodes Stratified by Tumor Differentiation of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1949-1955.	5.0	27
80	Influence of sampling schedules on [¹⁷⁷ Lu]Lu-PSMA dosimetry. <i>EJNMMI Physics</i> , 2020, 7, 41.	2.7	27
81	Evaluation of ¹⁸ F-Fluoride PET/MR and PET/CT in Patients with Foot Pain of Unclear Cause. <i>Journal of Nuclear Medicine</i> , 2015, 56, 430-435.	5.0	25
82	¹¹ C-choline PET/CT and whole-body MRI including diffusion-weighted imaging for patients with recurrent prostate cancer. <i>Oncotarget</i> , 2017, 8, 66516-66527.	1.8	25
83	Imaging Prostate Cancer With Prostate-Specific Membrane Antigen PET/CT and PET/MRI: Current and Future Applications. <i>American Journal of Roentgenology</i> , 2018, 211, 286-294.	2.2	25
84	Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7431.	4.1	25
85	Value of diffusion-weighted MR imaging in the diagnosis of lymph node metastases in patients with cholangiocarcinoma. <i>Abdominal Radiology</i> , 2016, 41, 1937-1941.	2.1	24
86	Salvage Surgery in Patients with Local Recurrence After Radical Prostatectomy. <i>European Urology</i> , 2021, 79, 537-544.	1.9	23
87	Whole-body uptake classification and prostate cancer staging in ⁶⁸ Ga-PSMA-11 PET/CT using dual-tracer learning. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 517-526.	6.4	23
88	Visualization of stress fractures of the foot using PET-MRI: a feasibility study. <i>European Journal of Medical Research</i> , 2015, 20, 99.	2.2	22
89	Mechanisms of Resistance to Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2021, 62, jnumed.120.256263.	5.0	22
90	Regional Lymph Node Metastasis on Prostate Specific Membrane Antigen Positron Emission Tomography Correlates with Decreased Biochemical Recurrence-Free and Therapy-Free Survival after Radical Prostatectomy: A Retrospective Single-Center Single-Arm Observational Study. <i>Journal of Urology</i> , 2021, 205, 1663-1670.	0.4	22

#	ARTICLE	IF	CITATIONS
91	PSMA-Ligand PET for Early Castration-Resistant Prostate Cancer: A Retrospective Single-Center Study. <i>Journal of Nuclear Medicine</i> , 2021, 62, 88-91.	5.0	21
92	Whole-Body [18F]-FDG-PET/MRI for Oncology: A Consensus Recommendation. <i>Nuklearmedizin - Nuclear Medicine</i> , 2019, 58, 68-76.	0.7	20
93	Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy. <i>BMC Cancer</i> , 2020, 20, 362.	2.6	20
94	PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study. <i>Journal of Nuclear Medicine</i> , 2022, 63, 76-80.	5.0	20
95	Identification of treatment-induced vulnerabilities in pancreatic cancer patients using functional model systems. <i>EMBO Molecular Medicine</i> , 2022, 14, e14876.	6.9	20
96	PSMA Theranostics Using PET and Subsequent Radioguided Surgery in Recurrent Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e549-e552.	1.9	19
97	Can the Injected Dose Be Reduced in 68Ga-PSMA-11 PET/CT While Maintaining High Image Quality for Lesion Detection?. <i>Journal of Nuclear Medicine</i> , 2020, 61, 189-193.	5.0	19
98	Mapping Prostate Cancer Lesions Before and After Unsuccessful Salvage Lymph Node Dissection Using Repeat PSMA PET. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1037-1042.	5.0	19
99	Prostate-specific membrane antigen-guided salvage lymph node dissection in recurrent prostate cancer. <i>Current Opinion in Urology</i> , 2018, 28, 191-196.	1.8	16
100	Comparative Preclinical Biodistribution, Dosimetry, and Endoradiotherapy in Metastatic Castration-Resistant Prostate Cancer Using ¹⁹ F/ ¹⁷⁷ Lu-rhPSMA-7.3 and ¹⁷⁷ Lu-PSMA I&T. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1106-1111.	5.0	16
101	Identification of PCWG3 Target Populations Is More Accurate and Reproducible with PSMA PET Than with Conventional Imaging: A Multicenter Retrospective Study. <i>Journal of Nuclear Medicine</i> , 2021, 62, 675-678.	5.0	16
102	Automated synthesis of [18F]Ga-rhPSMA-7/-7.3: results, quality control and experience from more than 200 routine productions. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2021, 6, 4.	3.9	16
103	PSMA PET for the Assessment of Metastatic Hormone-Sensitive Prostate Cancer Volume of Disease. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1747-1750.	5.0	16
104	Value of PET imaging for radiation therapy. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 1-23.	2.0	16
105	PET/MR in Oncology: Non- ¹⁸ F-FDG Tracers for Routine Applications. <i>Journal of Nuclear Medicine</i> , 2014, 55, 25S-31S.	5.0	15
106	Whole-Body [18F]-FDG-PET/MRI for Oncology: A Consensus Recommendation. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2019, 191, 289-297.	1.3	15
107	First experiences with Lu-177 PSMA therapy in combination with Pembrolizumab or after pretreatment with Olaparib in single patients. <i>Journal of Nuclear Medicine</i> , 2021, 62, jnumed.120.249029.	5.0	15
108	Utility of ¹⁸ F-rhPSMA-7.3 PET for Imaging of Primary Prostate Cancer and Preoperative Efficacy in N-Staging of Unfavorable Intermediate- to Very High-Risk Patients Validated by Histopathology. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1334-1342.	5.0	15

#	ARTICLE	IF	CITATIONS
109	From NETTER to PETER: PSMA-Targeted Radioligand Therapy. <i>Journal of Nuclear Medicine</i> , 2017, 58, 9-10.	5.0	14
110	Detection Efficacy of ¹⁸ F- α -PSMA- α -7.3 PET/CT and Impact on Management in Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Before Potential Salvage Treatment. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1719-1726.	5.0	14
111	Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol. <i>BMC Cancer</i> , 2021, 21, 512.	2.6	14
112	Safety of PSMA-Targeted Molecular Radioligand Therapy with ¹⁷⁷ Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312). <i>Journal of Nuclear Medicine</i> , 2021, 62, 1447-1456.	5.0	14
113	⁶⁸ Ga-labeled Prostate-specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Imaging: The New Kid on the Block "Early or Too Early to Draw Conclusions?". <i>European Urology</i> , 2016, 70, 938-940.	1.9	13
114	Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [⁶⁸ Ga]PSMA-PET-guided metastasis-directed therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2328-2338.	6.4	13
115	Pretherapeutic Comparative Dosimetry of ¹⁷⁷ Lu-rhPSMA-7.3 and ¹⁷⁷ Lu-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2022, 63, 833-839.	5.0	13
116	PSMA-PET for Lymph Node Detection in Recurrent Prostate Cancer: How do we use the Magic Bullet?. <i>Theranostics</i> , 2017, 7, 2046-2047.	10.0	12
117	PSMA-ligand uptake can serve as a novel biomarker in primary prostate cancer to predict outcome after radical prostatectomy. <i>EJNMMI Research</i> , 2021, 11, 76.	2.5	12
118	Technical Note: Optimal sampling schedules for kidney dosimetry based on the hybrid planar/SPECT method in ¹⁷⁷ Lu- α -PSMA therapy. <i>Medical Physics</i> , 2019, 46, 5861-5866.	3.0	11
119	Combining ⁶⁸ Ga-PSMA-PET/CT-Directed and Elective Radiation Therapy Improves Outcome in Oligorecurrent Prostate Cancer: A Retrospective Multicenter Study. <i>Frontiers in Oncology</i> , 2021, 11, 640467.	2.8	11
120	[¹⁸ F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinoma. <i>EJNMMI Research</i> , 2021, 11, 70.	2.5	11
121	Evaluation of SUV normalized by lean body mass (SUL) in ⁶⁸ Ga-PSMA11 PET/CT: a bi-centric analysis. <i>EJNMMI Research</i> , 2019, 9, 103.	2.5	11
122	RESIST-PC phase 2 trial: ¹⁷⁷ Lu-PSMA-617 radionuclide therapy for metastatic castrate-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5028-5028.	1.6	11
123	Positron emission tomography imaging in urological oncology: Current aspects and developments. <i>International Journal of Urology</i> , 2018, 25, 912-921.	1.0	10
124	Diagnostic performance of quantitative and qualitative parameters for the diagnosis of aortic graft infection using [¹⁸ F]-FDG PET/CT. <i>Journal of Nuclear Cardiology</i> , 2021, 28, 2220-2228.	2.1	10
125	Important pharmacokinetic parameters for individualization of ¹⁷⁷ Lu- α -PSMA therapy: A global sensitivity analysis for a physiologically-based pharmacokinetic model. <i>Medical Physics</i> , 2021, 48, 556-568.	3.0	10
126	A population-based method to determine the time-integrated activity in molecular radiotherapy. <i>EJNMMI Physics</i> , 2021, 8, 82.	2.7	10

#	ARTICLE	IF	CITATIONS
127	The sodium iodide symporter (NIS) as theranostic gene: its emerging role in new imaging modalities and non-viral gene therapy. <i>EJNMMI Research</i> , 2022, 12, 25.	2.5	10
128	[11C]Choline PET/CT in therapy response assessment of a neoadjuvant therapy in locally advanced and high risk prostate cancer before radical prostatectomy. <i>Oncotarget</i> , 2016, 7, 63747-63757.	1.8	9
129	Fully integrated whole-body [¹⁸ F]-fludeoxyglucose positron emission tomography/magnetic resonance imaging in therapy monitoring of giant cell arteritis. <i>European Heart Journal</i> , 2016, 37, 576-576.	2.2	9
130	Re: Lars BudÅus, Sami-Ramzi Leyh-Bannurah, Georg Salomon, et al. Initial Experience of 68Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy. <i>Eur Urol</i> 2016;69:393â€“6. <i>European Urology</i> , 2016, 70, e37-e38.	1.9	9
131	Pitfalls in Ga-68-PSMA-PET/CT: incidental finding of parathyroid adenoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1041-1041.	6.4	9
132	Feasibility and Outcome of PSMA-PET-Based Dose-Escalated Salvage Radiotherapy Versus Conventional Salvage Radiotherapy for Patients With Recurrent Prostate Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 715020.	2.8	9
133	Multimodal imaging for radiation therapy planning in patients with primary prostate cancer. <i>Physics and Imaging in Radiation Oncology</i> , 2018, 8, 8-16.	2.9	8
134	Gallium-68 HBED-CC-PSMA Positron Emission Tomography/Magnetic Resonance Imaging for Prostate Fusion Biopsy. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 245-247.	1.9	8
135	Almost 10Âyears of PET/MR attenuation correction: the effect on lesion quantification with PSMA: clinical evaluation on 200 prostate cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 543-553.	6.4	8
136	Is Hypoxia a Factor Influencing PSMA-Directed Radioligand Therapy?â€”An In Silico Study on the Role of Chronic Hypoxia in Prostate Cancer. <i>Cancers</i> , 2021, 13, 3429.	3.7	8
137	Prospective head-to-head comparison of 18F-fluciclovine and 68Ga-PSMA-11 PET/CT for localization of prostate cancer biochemical recurrence after primary prostatectomy.. <i>Journal of Clinical Oncology</i> , 2019, 37, 15-15.	1.6	8
138	Validation of ¹⁸ F-rhPSMA-7 and ¹⁸ F-rhPSMA-7.3 PET Imaging Results with Histopathology from Salvage Surgery in Patients with Biochemical Recurrence of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1809-1814.	5.0	8
139	Hyperkalemia in patients treated with endoradiotherapy combined with amino acid infusion is associated with severe metabolic acidosis. <i>EJNMMI Research</i> , 2018, 8, 17.	2.5	6
140	Practice changing for prostate cancer: a vision of the future. <i>Nature Reviews Urology</i> , 2019, 16, 71-72.	3.8	6
141	Cytoreductive radical prostatectomy after chemohormonal therapy in patients with primary metastatic prostate cancer. <i>Asian Journal of Urology</i> , 2022, 9, 69-74.	1.2	6
142	Accuracy of 68Ga-PSMA11 PET/CT on recurrent prostate cancer: Preliminary results from a phase 2/3 prospective trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5001-5001.	1.6	6
143	Narrative review: prostate-specific membrane antigen-radioligand therapy in metastatic castration-resistant prostate cancer. <i>Translational Andrology and Urology</i> , 2021, 10, 3963-3971.	1.4	6
144	Exceptional 4-year response to 177Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2212-2213.	6.4	5

#	ARTICLE	IF	CITATIONS
145	Positive predictive value and correct detection rate of ¹⁸ F-rhPSMA-7 PET in biochemically recurrent prostate cancer validated by composite reference standard. Journal of Nuclear Medicine, 2021, 62, jnumed.120.255661.	5.0	5
146	First Experience Using ¹⁸ F-Fluorobenguane PET Imaging in Patients with Suspected Pheochromocytoma or Paraganglioma. Journal of Nuclear Medicine, 2021, 62, 479-485.	5.0	5
147	Nuclear Medicine beyond VISION. Journal of Nuclear Medicine, 2021, 62, jnumed.121.262441.	5.0	5
148	Study evaluating metastatic castrate resistant prostate cancer (mCRPC) treatment using ¹⁷⁷ Lu-PNT2002 PSMA therapy after second-line hormonal treatment (SPLASH).. Journal of Clinical Oncology, 2021, 39, TPS5087-TPS5087.	1.6	5
149	The Influence of Specific Activity on the Biodistribution of 18F-rhPSMA-7.3: A Retrospective Analysis of Clinical Positron Emission Tomography Data. Journal of Nuclear Medicine, 2021, , jnumed.121.262471.	5.0	5
150	Pre-test 68Ga-PSMA-ligand PET/CT positivity in early biochemical recurrent prostate cancer after radical prostatectomyâ€”validation of a prediction model. EJNMMI Research, 2020, 10, 6.	2.5	5
151	Temporary reactive response of axillary lymph nodes to COVID-19 vaccination on ¹⁸ F-rhPSMA-7.3 PET/CT in patients with prostate cancer. Journal of Nuclear Medicine, 2022, , jnumed.121.263758.	5.0	5
152	PSMA PET tumor-to-salivary glands ratio (PSG score) to predict response to Lu-177 PSMA radioligand therapy: An international multicenter retrospective study.. Journal of Clinical Oncology, 2022, 40, 5043-5043.	1.6	5
153	What is the best PET target for early biochemical recurrence of prostate cancer?â€”Authorsâ€™ reply. Lancet Oncology, The, 2019, 20, e609-e610.	10.7	4
154	Double-strand breaks in lymphocyte DNA of humans exposed to [18F]fluorodeoxyglucose and the static magnetic field in PET/MRI. EJNMMI Research, 2020, 10, 43.	2.5	4
155	Initial evaluation of [18F]-FACBC for PET imaging of multiple myeloma. EJNMMI Research, 2022, 12, 4.	2.5	4
156	Preclinical biodistribution and dosimetry and human biodistribution comparing 18F-rhPSMA-7 and single isomer 18F-rhPSMA-7.3. EJNMMI Research, 2022, 12, 8.	2.5	4
157	Diagnosis and Treatment of Prostate Cancer: What Americans Can Learn From International Oncologists. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 344-357.	3.8	3
158	Incidental Finding of Colon Carcinoma Related to High Uptake in 18F-PSMA-1007 PET. Clinical Nuclear Medicine, 2020, 45, 561-562.	1.3	3
159	Multiparametric 18Fâ€”FDG PET/MR follow-up in a patient with autoimmune pancreatitis. European Journal of Hybrid Imaging, 2017, 1, 11.	1.5	2
160	Interim PSMA PET/CT for response evaluation during LuPSMA treatment in mCRPC (INTERIM PET): An explorative, multicenter study.. Journal of Clinical Oncology, 2021, 39, 5066-5066.	1.6	2
161	Value of PET imaging for radiation therapy. Nuklearmedizin - NuclearMedicine, 2021, 60, 326-343.	0.7	2
162	Impact of 68Ga-PSMA-11 PET on the management of biochemically recurrent prostate cancer in a prospective single-arm clinical trial.. Journal of Clinical Oncology, 2020, 38, 292-292.	1.6	2

#	ARTICLE	IF	CITATIONS
163	¹⁸ F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Curative-Intent Radiation Therapy: A Bicentric Retrospective Study. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1208-1214.	5.0	2
164	Safety and survival outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177 ¹⁷⁷ Lu-PSMA after radium-223 (²²³ Ra): Interim analysis of the RALU study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5040-5040.	1.6	2
165	A rare case of polyostotic fibrous dysplasia detected on 18F-rhPSMA-7 PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2927-2929.	6.4	1
166	Clinical experience with 100 consecutive patients treated with Lu-177-labeled PSMA-I&T radioligand therapy for metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 206-206.	1.6	1
167	An in silico study on the effect of the radionuclide half-life on PET/CT imaging with PSMA-targeting radioligands. <i>Nuklearmedizin - NuclearMedicine</i> , 2021, 60, 33-37.	0.7	1
168	Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP): An international multicenter study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 42-42.	1.6	1
169	Tumor Sink effect: Myth or Reality?. <i>Journal of Nuclear Medicine</i> , 2022, , jnumed.122.264119.	5.0	1
170	A PET for All Seasons: 18 F-Fluorodeoxyglucose to Characterize Inflammation and Malignancy in Retroperitoneal Fibrosis?. <i>European Urology</i> , 2017, 71, 934-935.	1.9	0
171	Multimodal therapy in oligometastatic prostate cancer: A glimpse into the future?. <i>Asian Journal of Urology</i> , 2021, 8, 248-250.	1.2	0
172	A survey among German-speaking radiation oncologists on PET-based radiotherapy of prostate cancer. <i>Radiation Oncology</i> , 2021, 16, 82.	2.7	0
173	PSMA-targeted imaging of prostate cancer: evolution of a success story. <i>Asian Journal of Andrology</i> , 2017, 19, 388.	1.6	0
174	Oncological and postoperative outcome of salvage PSMA-radioguided surgery in recurrent prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 270-270.	1.6	0
175	Prospective head-to-head comparative phase 3 study between ¹⁸ F-fluciclovine and ⁶⁸ Ga-PSMA-11 PET/CT in patients with early biochemical recurrence of prostate cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5014-5014.	1.6	0
176	Reply by Authors. <i>Journal of Urology</i> , 2019, 202, 1181-1181.	0.4	0
177	Impact of 68Ga-PSMA-11 PET/CT on staging and management of prostate cancer patients in various clinical settings.. <i>Journal of Clinical Oncology</i> , 2020, 38, 26-26.	1.6	0
178	Cohort study of oligorecurrent prostate cancer patients: Oncological outcomes of patients treated with salvage lymph node dissection via PSMA radioguided surgery.. <i>Journal of Clinical Oncology</i> , 2022, 40, 106-106.	1.6	0
179	Cohort study of patients with oligorecurrent prostate cancer: Oncological outcomes of patients treated with salvage lymph node dissection via PSMA radioguided surgery.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5009-5009.	1.6	0